The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in Table 3. Prophylaxis and treatment study results for each surfactant are combined. (See Table 3.)
![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled at 5 centers that participated in the Infasurf versus Exosurf Neonatal controlled t rials demonstrated significant developmental delays in equal percentages of Infasurf and Exosurf Neonatal patients.
View ADR Monitoring Form